Neurizon Therapeutics Limited has released a press release.
PharmAust Appendix 4C and Shareholders Update
Filed with ASX ·
6ix hasn’t read this filing yet.
Neurizon Therapeutics Limited on 6ix
Story so far
Earlier from Neurizon Therapeutics
- PharmAust and Elanco Execute Data Sharing Agreement
- Optimisation of Monepantel Uptake
- Monepantel Principal Metabolite Shows Anti-Cancer Activity
- PharmAust Develops Method for MPL/Analogue Manufacture
- GMP Tablet Manufacture Commences for Canine Clinical Trials
Later from Neurizon Therapeutics
- PharmAust Completes Scaled Manufacture of Monepantel Tablets
- PharmAust Signs Agreement for US Phase I Trials in Dogs
- PAA Completes Successful Taste Mask Testing of New Tablet
- Non-Renounceable Rights Offer
- Phase I Dog Trial with New Monepantel Tablets Commences
Follow Neurizon Therapeutics into a list and get an email when it puts out news.
Follow Neurizon Therapeutics